BioSpace News Archive

Clene Inc. today reported that it has received a positive opinion for its submission requesting Orphan Drug Designation for CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS).

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to LUMRYZ, also known as FT218.

Mydecine Innovations Group Inc. announced it has successfully synthesized multiple short-acting MDMA analogs.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a request for “scientific advice review” to the European Medicines Agency (the “EMA”) and more specifically the Committee for Medicinal Products for Human Use (the “CHMP”) regarding the XRx-008 program.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today published its 2021 Corporate Responsibility Report.

ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased a MRIdian MRI-Guided Radiation Therapy System to complete its newly built comprehensive cancer center in Yamane, Hidaka-City.

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose “Pepe” Carmona to its Board of Directors.

Protagonist Therapeutics, Inc. reported that on July 15, 2022, it issued an inducement award to Karen Peterson, the Company’s recently hired Vice President, Controller, in accordance with the terms of Ms. Peterson’s employment offer letter.

Viking Therapeutics, Inc. today announced that the FDA has lifted the clinical hold placed on the clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).

Endotronix, Inc. announced plans to relocate and expand their headquarters in Naperville, Illinois to support the full U.S. commercial launch of its Cordella™ Heart Failure System and Pulmonary Artery Sensor, pending pre-market approval of the sensor by the U.S. Food & Drug Administration.